Title:
血液癌前駆細胞を障害する方法およびその関連化合物
Document Type and Number:
Japanese Patent JP2004509835
Kind Code:
A
Abstract:
Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R alpha or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells.; These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics.
Inventors:
Craig T. Jordan
Application Number:
JP2001564791A
Publication Date:
April 02, 2004
Filing Date:
March 06, 2001
Export Citation:
Assignee:
University of Kentucky Research Foundation
International Classes:
A61K33/00; A61K33/18; A61K39/395; A61K45/00; A61K45/06; A61K51/10; A61P7/00; A61P19/00; A61P35/00; A61P35/02; A61P35/04; G01N33/574; A61P43/00; C07K16/28; (IPC1-7): A61K45/00; A61K33/00; A61K33/18; A61K39/395; A61K45/06; A61P7/00; A61P19/00; A61P35/02; A61P35/04; A61P43/00; G01N33/574
Foreign References:
| WO1997024373A1 | 1997-07-10 |
Other References:
JPN5003007503; Ｃ． ＣＨＡＮ: ＢＬＯＯＤ Ｖ８８Ｎ４, 19960815, Ｐ１４４５-１４５６
JPN5003007503; Ｃ． ＣＨＡＮ: ＢＬＯＯＤ Ｖ８８Ｎ４, 19960815, Ｐ１４４５-１４５６
JPN5003007501; Ｑ． ＳＵＮ: ＢＬＯＯＤ Ｖ８７Ｎ１, 19960101, Ｐ８３-９２
JPN5003007502; Ｃ． ＪＯＲＤＡＮ: ＢＬＯＯＤ Ｖ９４Ｎ１０ＳＵＰＰＬ１（ＰＡＲＴ１ ＯＦ ２）, 19991115, Ｐ６７Ａ
JPN6010063261; Ｋｏｕｂｅｋ Ｋ ｅｔ ａｌ: Ｅｕｒ Ｊ Ｈａｅｍａｔｏｌ ６３, 1999, ｐ．１-１０
JPN6011063868; 山口俊晴 外３名: '腫瘍マーカーを利用した免疫ミサイル療法' 日本臨床 第５４巻，第６号, 1996, ｐ．１６７４-１６７９
JPN6011063870; 山口俊晴 外１１名: '癌のターゲティング療法の進歩 モノクローナル抗体を利用した癌ミサイル療法のＤＤＳ' 日本臨床 第５６巻，第３号, 1998, ｐ．６３８-６４３
JPN6011063873; 塚崎克己 外２名: '癌化学療法の現状と将来 新しいミサイル療法' 産科と婦人科 第６２巻，第１２号, 1995, ｐ．１７２１-１７２９
JPN5003007503; Ｃ． ＣＨＡＮ: ＢＬＯＯＤ Ｖ８８Ｎ４, 19960815, Ｐ１４４５-１４５６
JPN5003007501; Ｑ． ＳＵＮ: ＢＬＯＯＤ Ｖ８７Ｎ１, 19960101, Ｐ８３-９２
JPN5003007502; Ｃ． ＪＯＲＤＡＮ: ＢＬＯＯＤ Ｖ９４Ｎ１０ＳＵＰＰＬ１（ＰＡＲＴ１ ＯＦ ２）, 19991115, Ｐ６７Ａ
JPN6010063261; Ｋｏｕｂｅｋ Ｋ ｅｔ ａｌ: Ｅｕｒ Ｊ Ｈａｅｍａｔｏｌ ６３, 1999, ｐ．１-１０
JPN6011063868; 山口俊晴 外３名: '腫瘍マーカーを利用した免疫ミサイル療法' 日本臨床 第５４巻，第６号, 1996, ｐ．１６７４-１６７９
JPN6011063870; 山口俊晴 外１１名: '癌のターゲティング療法の進歩 モノクローナル抗体を利用した癌ミサイル療法のＤＤＳ' 日本臨床 第５６巻，第３号, 1998, ｐ．６３８-６４３
JPN6011063873; 塚崎克己 外２名: '癌化学療法の現状と将来 新しいミサイル療法' 産科と婦人科 第６２巻，第１２号, 1995, ｐ．１７２１-１７２９
Attorney, Agent or Firm:
Chika Takagi
Kosuke Nishimura
Hiroshi Sugimoto
Kosuke Nishimura
Hiroshi Sugimoto